HRP20050933A2 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
HRP20050933A2
HRP20050933A2 HR20050933A HRP20050933A HRP20050933A2 HR P20050933 A2 HRP20050933 A2 HR P20050933A2 HR 20050933 A HR20050933 A HR 20050933A HR P20050933 A HRP20050933 A HR P20050933A HR P20050933 A2 HRP20050933 A2 HR P20050933A2
Authority
HR
Croatia
Prior art keywords
organic compounds
compounds
zwitterions
muscarinic
receptor
Prior art date
Application number
HR20050933A
Other languages
English (en)
Croatian (hr)
Inventor
Paul Collingwood Stephen
Cox Brian
Baettig Urs
Bhalay Gurdip
James Devereux Nicholas
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33420896&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20050933(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0324887A external-priority patent/GB0324887D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HRP20050933A2 publication Critical patent/HRP20050933A2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
HR20050933A 2003-05-02 2004-04-30 Organic compounds HRP20050933A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0310232 2003-05-02
GB0324887A GB0324887D0 (en) 2003-10-24 2003-10-24 Organic compounds
PCT/EP2004/004605 WO2004096800A2 (en) 2003-05-02 2004-04-30 Quinuclidine derivatives binding to mucarinic m3 receptors

Publications (1)

Publication Number Publication Date
HRP20050933A2 true HRP20050933A2 (en) 2006-12-31

Family

ID=33420896

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20050933A HRP20050933A2 (en) 2003-05-02 2004-04-30 Organic compounds

Country Status (31)

Country Link
US (2) US20070060563A1 (is)
EP (1) EP1631569B1 (is)
JP (1) JP4416786B2 (is)
KR (1) KR100896544B1 (is)
AR (1) AR044134A1 (is)
AT (1) ATE440840T1 (is)
AU (1) AU2004234069B2 (is)
BR (1) BRPI0410238A (is)
CA (1) CA2523436C (is)
CL (1) CL2004000918A1 (is)
CO (1) CO5700782A2 (is)
CY (1) CY1109655T1 (is)
DE (1) DE602004022805D1 (is)
DK (1) DK1631569T3 (is)
EC (1) ECSP056134A (is)
ES (1) ES2331185T3 (is)
HR (1) HRP20050933A2 (is)
IL (1) IL171591A (is)
IS (1) IS2746B (is)
MA (1) MA27775A1 (is)
MX (1) MXPA05011739A (is)
MY (1) MY142652A (is)
NO (1) NO20055688L (is)
NZ (1) NZ542995A (is)
PE (1) PE20050465A1 (is)
PL (1) PL1631569T3 (is)
PT (1) PT1631569E (is)
RU (1) RU2363700C2 (is)
SI (1) SI1631569T1 (is)
TW (1) TWI340139B (is)
WO (1) WO2004096800A2 (is)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2239546B1 (es) * 2004-03-15 2006-12-01 Almirall Prodesfarma, S.A. Nuevos esteres de quinuclidina cuaternizados.
GB0410712D0 (en) 2004-05-13 2004-06-16 Novartis Ag Organic compounds
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0428416D0 (en) * 2004-12-24 2005-02-02 Novartis Ag Organic compounds
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
EP1900737A1 (en) * 2006-08-31 2008-03-19 Novartis AG Polymorph of (R)-3-(2-hydroxy-2,2-diphenyl-acetoxy)-1-(isoxazol-3-ylcarbamoyl-methyl)-1-azonia-bicyclo-[2.2.2]octane bromide
EP1894568A1 (en) * 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
WO2008075005A1 (en) * 2006-12-19 2008-06-26 Astrazeneca Ab Quinuclidinol derivatives as muscarinic receptor antagonists
EP1950196A1 (de) * 2007-01-29 2008-07-30 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Herstellung von Ammoniumhexafluorophosphaten
JP5656288B2 (ja) 2007-09-07 2015-01-21 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ムスカリン受容体アンタゴニストとして有用なグアジニン含有化合物
US8017617B2 (en) * 2007-12-14 2011-09-13 Theravance, Inc. Amidine-containing compounds useful as muscarinic receptor antagonists
EP2231642B1 (en) 2008-01-11 2013-10-23 Novartis AG Pyrimidines as kinase inhibitors
GB0808709D0 (en) * 2008-05-13 2008-06-18 Astrazeneca Ab New combination 295
NZ589091A (en) * 2008-05-13 2011-07-29 Astrazeneca Ab Quinuclidine derivatives as muscarinic m3 receptor antagonists
CN102908624A (zh) * 2008-05-13 2013-02-06 阿斯利康(瑞典)有限公司 包含毒蕈碱性受体拮抗剂和β2-肾上腺素受体激动剂的药物产品
US20090326004A1 (en) 2008-06-03 2009-12-31 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
WO2009153536A1 (en) * 2008-06-17 2009-12-23 Argenta Discovery Limited 1-aza-bicyclo [2.2.2] octane derivatives useful as muscarinic receptor antagonists
GB0811100D0 (en) * 2008-06-17 2008-07-23 Astrazeneca Ab New combination
CN102947300B (zh) * 2010-06-22 2016-09-21 奇斯药制品公司 生物碱氨基酯衍生物及其药物组合物
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
AU2012220572A1 (en) 2011-02-25 2013-08-29 Irm Llc Compounds and compositions as trk inhibitors
JP2011195593A (ja) * 2011-06-30 2011-10-06 Astrazeneca Ab ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体
WO2013098145A1 (en) * 2011-12-30 2013-07-04 Chiesi Farmaceutici S.P.A. Quinuclidine esters of 1-azaheterocyclylacetic acid as antimuscarinic agents, process for their preparation and medicinal compositions thereof
CN104470515B (zh) 2012-05-03 2016-12-07 圣路易斯药学院 用于增加神经营养肽的组合物和方法
TWI647227B (zh) * 2013-02-28 2019-01-11 日商安斯泰來製藥股份有限公司 ２－醯胺噻唑衍生物或其鹽
CZ306791B6 (cs) 2013-10-29 2017-07-12 Zentiva, K.S. Průmyslově využitelný způsob přípravy aklidinium bromidu o vysoké čistotě
PT108370B (pt) * 2015-03-30 2018-10-25 Hovione Farm S A Processo de preparação de brometo de aclidínio
PT3111978T (pt) 2015-07-03 2021-12-06 Novartis Ag Inalador adaptado para ler informação armazenada num meio de armazenamento de dados de um recipiente

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1219606A (en) * 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
DK534178A (da) * 1977-12-16 1979-06-17 Interx Research Corp Anticholinerge midler med sektrtionshaemmende virkning
IT1230881B (it) * 1989-06-20 1991-11-08 Angeli Inst Spa Derivati del r(-) 3-chinuclidinolo
ES2165768B1 (es) * 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
CA2415468A1 (en) * 2000-07-11 2003-01-10 Yoshio Ogino Ester derivatives
CN1250545C (zh) * 2000-12-28 2006-04-12 阿尔米雷尔普罗迪斯制药有限公司 新的奎宁环衍生物类及含有这类衍生物的药物组合物
JP4505227B2 (ja) * 2001-12-20 2010-07-21 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ １−アルキル−１−アゾニアビシクロ［２．２．２］オクタンカルバメート誘導体およびムスカリンレセプターアンタゴニストとしてのそれらの使用
GB0424284D0 (en) * 2004-11-02 2004-12-01 Novartis Ag Organic compounds
EP1900737A1 (en) * 2006-08-31 2008-03-19 Novartis AG Polymorph of (R)-3-(2-hydroxy-2,2-diphenyl-acetoxy)-1-(isoxazol-3-ylcarbamoyl-methyl)-1-azonia-bicyclo-[2.2.2]octane bromide

Also Published As

Publication number Publication date
KR20060015572A (ko) 2006-02-17
TWI340139B (en) 2011-04-11
PL1631569T3 (pl) 2010-02-26
DE602004022805D1 (de) 2009-10-08
PE20050465A1 (es) 2005-07-18
DK1631569T3 (da) 2009-11-23
RU2363700C2 (ru) 2009-08-10
NO20055688L (no) 2006-01-09
CL2004000918A1 (es) 2005-02-11
MA27775A1 (fr) 2006-02-01
HK1087704A1 (en) 2006-10-20
US20100041887A1 (en) 2010-02-18
WO2004096800A3 (en) 2005-01-06
IS8158A (is) 2005-11-30
JP2006525267A (ja) 2006-11-09
CO5700782A2 (es) 2006-11-30
CY1109655T1 (el) 2014-08-13
MY142652A (en) 2010-12-15
JP4416786B2 (ja) 2010-02-17
SI1631569T1 (sl) 2010-01-29
PT1631569E (pt) 2009-11-26
MXPA05011739A (es) 2006-01-26
TW200505920A (en) 2005-02-16
US8168654B2 (en) 2012-05-01
ES2331185T3 (es) 2009-12-23
BRPI0410238A (pt) 2006-05-16
RU2005137360A (ru) 2006-07-27
IS2746B (is) 2011-08-15
AU2004234069A1 (en) 2004-11-11
EP1631569A2 (en) 2006-03-08
NZ542995A (en) 2009-02-28
AU2004234069B2 (en) 2008-02-21
NO20055688D0 (no) 2005-12-01
KR100896544B1 (ko) 2009-05-07
CA2523436C (en) 2011-11-01
AR044134A1 (es) 2005-08-24
IL171591A (en) 2010-11-30
US20070060563A1 (en) 2007-03-15
ATE440840T1 (de) 2009-09-15
CA2523436A1 (en) 2004-11-11
ECSP056134A (es) 2006-04-19
WO2004096800A2 (en) 2004-11-11
EP1631569B1 (en) 2009-08-26

Similar Documents

Publication Publication Date Title
NO20055688L (no) Organiske forbindelser
DE602004011199D1 (de) 5-phenylthiazolderivate und deren verwendung als p13-kinase-inhibitoren
ECSP055676A (es) Piperazinas heterocíclicas sustituidas para el tratamiento de la esquizofrenia
CY1116885T1 (el) Υποκατεστημενα παραγωγα κυκλοεξυλομεθυλιου
MEP45308A (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
SE0401971D0 (sv) Piperidne derivatives
MEP36508A (en) Triazolopyrazine derivatives useful as anti-cancer agents
CY1112960T1 (el) Παραγωγα ουριας, μεθοδοι για την παρασκευη τους και χρησεις αυτων
WO2007084595A3 (en) Carbocyclic and heterocyclic arylsulfones as gamma secretase inhibitors
BRPI0406762A (pt) Derivados de n-(1-benzil-2-oxo-2-(1-piperazinil)etil)-1-piperidincarb oxamida e compostos relacionados como antagonistas de cgrp, para tratamento de dores de cabeça
NO20081001L (no) Derivater av karboksamid som antagonister for muskarinisk reseptor
SE0401970D0 (sv) Novel compounds
SE0302139D0 (sv) Novel compounds
SE0303541D0 (sv) New compounds
BRPI0519292A2 (pt) compostos orgÂnicos
WO2009055629A3 (en) Cyclohexeneamide derivatives and their use as trpv1 antagonist
MXPA05013823A (es) Derivados de pirrolidinio y piperidino como ligandos para el receptor m3 muscarinico.
ATE411296T1 (de) Imidazolinderivate mit cb1-antagonistischer wirkung
ATE553095T1 (de) Neue imidazolderivate, deren herstellung und deren verwendung als intermediate zur herstellung von arzneimitteln und pestiziden
DE602004011204D1 (de) Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten.
ATE541839T1 (de) Pyrrolidiniumderivate als m3-muskarinische rezeptoren
SE0303280D0 (sv) Novel compounds
ATE409179T1 (de) Tetralin- und indanderivate und deren anwendungen als 5-ht-antagonisten
ATE543803T1 (de) 3-ä2-(3-azylamino-2-oxo-2h-pyridin-1- yl)acetylaminoü-4-oxopentansäurederivate und deren verwendung als caspase-inhibitoren
SE0302755D0 (sv) Novel compounds

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20110423

Year of fee payment: 8

OBST Application withdrawn